Newly-released Tendonitis Treatment Market analysis report by Future Market Insights shows that global sales of the Tendonitis Treatment Market in 2021 were held at US$ 193.7 billion. With a CAGR of 4.1%, the projected market growth during 2022 to 2032 is expected to be significantly higher than the historical. Tendonitis Therapy is expected to be the highest revenue-generating segment expected to grow at a CAGR of 4.3% from 2022 to 2032.
| Attribute | Details |
|---|---|
| Global Tendonitis Treatment Market (2022) | US$ 201.8 billion |
| Global Tendonitis Treatment Market (2032) | US$ 301.8 billion |
| Global Tendonitis Treatment Market CAGR (2022 to 2032) | 4.1% |
| The USA Tendonitis Treatment Market CAGR (2022 to 2032) | 4.4% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Tendonitis Treatment Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Tendonitis Treatment Market increased at around 3.8% CAGR.
Following the COVID-19 epidemic, the medical community altered existing treatment for tendonitis. Athletic injury-related costs and general companies fell due to lockdowns, severe travel restrictions, and a high infection load in medical care.
The 2020 coronavirus outbreak kept the treatment of tendonitis by doctors to a minimum, as fewer people could undergo the treatment. The popularity of day-to-day sports activities declined, and injuries in Achilles tendons did not increase as fast as expected. As a result, the tendonitis market faced less demand for treatment.
The market's growth may be boosted in the years ahead owing to increased acceptance of continual technological innovation, as more Americans suffer from geriatric diseases and people’s growing participation in sports. However, insufficient knowledge of this illness and rising treatment choices may have a negative effect on the market. Owing to these factors, Tendonitis Treatment Market is projected to grow at a CAGR of 4.1% over the coming 10 years.
The leading cause of soft tissue injuries worldwide and a major impact-rendering driver for the market is the rising incidence of sports-related injuries as a result of the rapid increase in sports activities. Furthermore, increasing career opportunities and a growing desire for fitness have increased the number of people who choose sports as a career or a hobby. As a result, their chances of getting hurt are expected to rise.
Furthermore, as various treatment options such as physical therapy, over-the-counter pain relievers, and various surgical procedures have become more widely available, the number of people seeking treatment has increased, assisting market growth. Physical therapy has emerged as the first-line treatment for tendonitis, as eccentric strengthening has been shown to be an effective treatment for a variety of chronic tendon conditions.
Clinical grafts currently used in tendon treatment have a number of limitations, and there is a high demand for alternative engineered tissue. As a result, innovative strategies such as tendon replacement and regeneration are in high demand to maintain market growth.
Principal Consultant
North America accounts for the highest expected market share during the forecast period. Because of the presence of major players and higher spending on healthcare advancements in the region, the market in North America is expected to dominate the global market.
People in North America are becoming more aware of the disease than in other parts of the world. North America is expected to dominate the global market due to well-established healthcare facilities and a growing geriatric population, as well as an increase in the number of orthopedic procedures.
Furthermore, the aging population pool, as well as improvements in healthcare and medical infrastructure, are expected to aid Asia Pacific's remarkable growth in the near future. Due to an increase in the number of tendonitis surgeries performed in the region, as well as rising disposable income.
The market in the region has significant growth opportunities due to the increasing penetration of local medical device manufacturers and a growing population suffering from tendonitis. Furthermore, ongoing research in this field, increasing products in the pipeline for tendonitis treatment, particularly in China and Japan, as well as an increasing number of sports-related injuries, are further driving the market.
The USATendonitis Treatment Market Analysis
The United States is expected to account for the highest market of US$ 36.8 billion by the end of 2032. This is attributable to a significant increase in research & development activities. Furthermore, advances in the healthcare industry have resulted in the development of new technologies and equipment, which is expected to boost the market in the United States even further.
Furthermore, the presence of well-known corporations, as well as early access to new and developing technology, is projected to aid the United States in maintaining its global market supremacy in the next years.
China Tendonitis Treatment Market Analysis
China will dominate the Asia Pacific market from 2022 to 2032, with a CAGR of 4.8%, approaching a market revenue of US$ 95.6 million by 2032. During the forecast period, the market is expected to witness an absolute dollar opportunity of US$ 36 million.
Japan Tendonitis Treatment Market Analysis
The market in Japan on other hand is expected to register a CAGR of 3.8% approaching the market revenue of US$ 30.2 million by 2032. Because of the developing healthcare infrastructure and the adoption of advanced technologies, the region is expected to account for lucrative market growth. Furthermore, rising disposable income and improved access to organized healthcare in developing countries like India and China are expected to boost the regional market over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The therapy treatment segment dominated the market in 2021, accounting for the most revenue with a 3.9% CAGR. It is due to the patients' growing preference for non-invasive therapies over surgical procedures for tendonitis treatment.
Physical therapy had the largest market share in the therapy segment, owing to the fact that it is the first line of treatment. In addition, other types of therapy, such as hot and cold therapy and shockwave therapy, have seen significant increases in demand in recent years.
Surgery is considered the last resort for tendonitis treatment when severe damage to tendons cannot be treated with pharmacological treatments. During the first 48 hours after an injury, however, cold therapy, including cold compresses, is usually effective. Tendonitis treatment options vary depending on the type of indication. Achilles tendonitis is the most common type of tendonitis, and the Achilles tendon is the largest tendon in the human body.
On basis of condition, because of the rising prevalence of Achilles tendonitis among athletes and sports players, the Achilles tendonitis segment dominated the market in 2021. Achilles tendonitis can be treated with both conservative and surgical procedures, depending on whether the condition is acute or chronic. The surgical treatment procedure is highly recommended by specialists in the case of individuals who have a full rupture. During the forecast period, the rising prevalence of tendonitis due to an increase in sports and occupational work injuries is expected to generate significant sales opportunities in the global market. Golfer's elbow, tennis elbow, jumper's knee, pitcher's elbow, Achilles tendonitis, and swimmer's shoulder are some of the health issues for which tendonitis treatment is used.
The market for tendonitis treatment is being driven by a large number of well-established and small domestic and international players. To expand their product portfolio and reach, the majority of companies are forming multiple partnerships, mergers, and acquisitions.
Merck and Co Inc, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Abbott, and Pfizer are some of the most well-known companies in the tendonitis treatment market. Major market players use a variety of methods to preserve their dominance, including high Research and Development (R&D) activity, global expansion strategies, broad product offers, and frequent introduction of advanced versions of existing items.
Some of the recent developments of key Tendonitis Treatment providers are as follows:
Similarly, the team at Future Market Insights has tracked recent developments related to companies offering Tendonitis Treatment, which is available in the full report.
The global market is worth more than US$ 193.7 billion at present.
The value of the market is projected to increase at a CAGR of around 4.1% from 2022 to 2032.
The value of the Tendonitis Treatment Market increased at a CAGR of around 3.8% from 2017 to 2021.
Increased incidence of tendonitis due to an aging population, demands preventive care, increasing awareness, increasing healthcare expenditure, quick treatments, sports, and occupational work injuries as well as sudden injuries caused by physical exercise and trauma are all driving the tendonitis treatment market forward.
The market in China is projected to expand at a CAGR of around 4.8% from 2022 to 2032.
While the market in South Korea is expected to grow at nearly 3.5%, the market in Japan is projected to register a CAGR of nearly 3.8% from 2022 to 2032.
1. Executive Summary | Tendonitis Treatment Market
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ million)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background and Foundation Data Points
4.1. Global Market (US$ million)
4.2. Market Opportunity Assessment (US$ million)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Market Growth
4.5.3. Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032
6.1. Historical Market Analysis, 2017 to 2021
6.2. Current and Future Market Projections, 2022 to 2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ million) Analysis, 2017 to 2021
7.2. Current and Future Market Value (US$ million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis By Treatment Type, 2017 to 2021
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Treatment Type, 2022 to 2032
8.3.1. Therapy
8.3.1.1. Hot and Cold Therapy
8.3.1.2. Physical Therapy
8.3.1.3. Shockwave Therapy
8.3.2. Surgery
8.4. Market Attractiveness Analysis By Treatment Type
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Condition
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) Analysis By Condition, 2017 to 2021
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Condition, 2022 to 2032
9.3.1. Tennis Elbow
9.3.2. Golfer’s Elbow
9.3.3. Pitcher’s Elbow
9.3.4. Jumper’s Knee
9.3.5. Swimmer’s Shoulder
9.3.6. Achilles Tendonitis
9.4. Market Attractiveness Analysis By Condition
10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
10.1. Introduction
10.2. Historical Market Size (US$ million) Analysis By Region, 2017 to 2021
10.3. Current Market Size (US$ million) & Analysis and Forecast By Region, 2022 to 2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
11.1. Introduction
11.2. Pricing Analysis
11.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
11.4.1. By Country
11.4.1.1. The USA
11.4.1.2. Canada
11.4.1.3. Rest of North America
11.4.2. By Treatment Type
11.4.3. By Condition
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Treatment Type
11.5.3. By Condition
12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
12.4.1. By Country
12.4.1.1. Brazil
12.4.1.2. Mexico
12.4.1.3. Rest of Latin America
12.4.2. By Treatment Type
12.4.3. By Condition
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Treatment Type
12.5.3. By Condition
13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
13.4.1. By Country
13.4.1.1. Germany
13.4.1.2. France
13.4.1.3. The United Kingdom
13.4.1.4. Italy
13.4.1.5. Spain
13.4.1.6. Nordic Countries
13.4.1.7. Rest of Europe
13.4.2. By Treatment Type
13.4.3. By Condition
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Treatment Type
13.5.3. By Condition
14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
14.4.1. By Country
14.4.1.1. China
14.4.1.2. Japan
14.4.1.3. South Korea
14.4.1.4. Rest of Asia Pacific
14.4.2. By Treatment Type
14.4.3. By Condition
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Treatment Type
14.5.3. By Condition
15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
15.4.1. By Country
15.4.1.1. GCC Countries
15.4.1.2. South Africa
15.4.1.3. Turkey
15.4.1.4. Rest of Middle East and Africa
15.4.2. By Treatment Type
15.4.3. By Condition
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Treatment Type
15.5.3. By Condition
16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis, By Key Countries
16.1.2. Global Vs. Country Growth Comparison
16.2. US Market Analysis
16.2.1. Value Proportion Analysis by Market Taxonomy
16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.2.2.1. By Treatment Type
16.2.2.2. By Condition
16.3. Canada Market Analysis
16.3.1. Value Proportion Analysis by Market Taxonomy
16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.3.2.1. By Treatment Type
16.3.2.2. By Condition
16.4. Mexico Market Analysis
16.4.1. Value Proportion Analysis by Market Taxonomy
16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.4.2.1. By Treatment Type
16.4.2.2. By Condition
16.5. Brazil Market Analysis
16.5.1. Value Proportion Analysis by Market Taxonomy
16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.5.2.1. By Treatment Type
16.5.2.2. By Condition
16.6. Germany Market Analysis
16.6.1. Value Proportion Analysis by Market Taxonomy
16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.6.2.1. By Treatment Type
16.6.2.2. By Condition
16.7. France Market Analysis
16.7.1. Value Proportion Analysis by Market Taxonomy
16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.7.2.1. By Treatment Type
16.7.2.2. By Condition
16.8. Italy Market Analysis
16.8.1. Value Proportion Analysis by Market Taxonomy
16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.8.2.1. By Treatment Type
16.8.2.2. By Condition
16.9. Spain Market Analysis
16.9.1. Value Proportion Analysis by Market Taxonomy
16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.9.2.1. By Treatment Type
16.9.2.2. By Condition
16.10. The United Kingdom Market Analysis
16.10.1. Value Proportion Analysis by Market Taxonomy
16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.10.2.1. By Treatment Type
16.10.2.2. By Condition
16.11. Nordic Countries Market Analysis
16.11.1. Value Proportion Analysis by Market Taxonomy
16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.11.2.1. By Treatment Type
16.11.2.2. By Condition
16.12. China Market Analysis
16.12.1. Value Proportion Analysis by Market Taxonomy
16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.12.2.1. By Treatment Type
16.12.2.2. By Condition
16.13. Japan Market Analysis
16.13.1. Value Proportion Analysis by Market Taxonomy
16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.13.2.1. By Treatment Type
16.13.2.2. By Condition
16.14. South Korea Market Analysis
16.14.1. Value Proportion Analysis by Market Taxonomy
16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.14.2.1. By Treatment Type
16.14.2.2. By Condition
16.15. GCC Countries Market Analysis
16.15.1. Value Proportion Analysis by Market Taxonomy
16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.15.2.1. By Treatment Type
16.15.2.2. By Condition
16.16. South Africa Market Analysis
16.16.1. Value Proportion Analysis by Market Taxonomy
16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.16.2.1. By Treatment Type
16.16.2.2. By Condition
16.17. Turkey Market Analysis
16.17.1. Value Proportion Analysis by Market Taxonomy
16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.17.2.1. By Treatment Type
16.17.2.2. By Condition
16.17.3. Competition Landscape and Player Concentration in the Country
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Concentration
17.3. Market Share Analysis of Top Players
17.4. Market Presence Analysis
17.4.1. By Regional footprint of Players
17.4.2. Product footprint by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Merck and Co Inc
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Sales Footprint
18.3.1.4. Strategy Overview
18.3.2. AstraZeneca
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Sales Footprint
18.3.2.4. Strategy Overview
18.3.3. Boehringer Ingelheim Pharmaceuticals
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Sales Footprint
18.3.3.4. Strategy Overview
18.3.4. Abbott
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Sales Footprint
18.3.4.4. Strategy Overview
18.3.5. Pfizer
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Sales Footprint
18.3.5.4. Strategy Overview
18.3.6. GlaxoSmithKline PLC
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Sales Footprint
18.3.6.4. Strategy Overview
18.3.7. Almatica Pharma, Inc.
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Sales Footprint
18.3.7.4. Strategy Overview
18.3.8. Teva Pharmaceuticals Industries
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Sales Footprint
18.3.8.4. Strategy Overview
Explore Healthcare Insights
View Reports
Tendonitis Treatment Market
